Specifically in melanoma, elevated serum IgG4 levels and IgG4+ B cells in patient circulation are associated with worse clinical outcomes, implying a bias toward an alternative rather than an IgE-biased response associated with melanoma cancer growth.30,31. The gene discussed is IGHE; the disease is melanoma.